Plasma amyloid-beta levels are significantly associated with a transition toward Alzheimer's disease as measured by cognitive decline and change in neocortical amyloid burden

Manuscript Number: 

13-1802R1

Author(s): 
David Ames, Samantha C. Burnham, Ashley I. Bush, James D. Doecke, Kathryn A. Ellis, S. Lance Macaulay, Ralph N. Martins, Paul Maruff, Colin L. Masters, Alan Rembach, Christopher C. Rowe, Victor L. Villemagne, Andrew D. Watt, William Wilson

Disclosures

David Ames

  • Consulting Fees:
    Prana trial DSMB - approx. $900 in 2 years
    Lecture Fees:
    Pfizer Master Class 2012
    Grants
    • Agency: 
      Pfizer, Prana
      Dates: 
      2011, 2012, 2013

Samantha C. Burnham

  • Nothing to Disclose

Ashley I. Bush

  • Consulting Fees:
    CMD LLC
    Equity:
    Prana Biotechnology Ltd Mesoblast Ltd Cogstate Ltd
    Lecture Fees:
    Servier
    Patents/Royalties
    Out licensed patent to Prana and Cogstate

James D. Doecke

  • Nothing to Disclose

Kathryn A. Ellis

  • Nothing to Disclose

S. Lance Macaulay

  • Equity:
    Holds stocks in companies that are unrelated to anything in the area of research covered by this Journal article.
    Patents/Royalties
    AIBL receives support from Merck for CSF collection,GE for imaging and biomarker discovery and Janssen for biomarker discovery. It has received funding from Pfizer for biomarker discovery. AIBL has been supported by CSIRO and the Science and Industry Endowment fund Australia. See www.aibl.csiro.au

Ralph N. Martins

  • Nothing to Disclose

Paul Maruff

  • Nothing to Disclose

Colin L. Masters

  • Equity:
    prana biotechnology
    Grants
    • Agency: 
      prana biotech
      Dates: 
      current

Alan Rembach

  • Nothing to Disclose

Christopher C. Rowe

  • Nothing to Disclose

Victor L. Villemagne

  • Nothing to Disclose

Andrew D. Watt

  • Nothing to Disclose

William Wilson

  • Nothing to Disclose